Buccal midazolam for treatment of prolonged seizures in children

Basit Öğe Kaydı
dc.authoridYakıncı, Mehmet Cengiz/0000-0001-5930-4269
dc.authoridKutlu, Nurettin Onur/0000-0002-3306-6570
dc.authorwosidYakıncı, Mehmet Cengiz/ABI-7519-2020
dc.authorwosidKutlu, Nurettin Onur/AAW-6196-2021
dc.contributor.authorKutlu, NO
dc.contributor.authorDogrul, M
dc.contributor.authorYakinci, C
dc.contributor.authorSoylu, H
dc.date.accessioned2024-08-04T20:13:18Z
dc.date.available2024-08-04T20:13:18Z
dc.date.issued2003
dc.departmentİnönü Üniversitesien_US
dc.description.abstractMidazolam is a relatively new anticonvulsive agent in the benzodiazepine group. It has a short onset of duration and is practical for use, providing several alternatives such as intravenous, intramuscular, and intranasal routes. The buccal route could be an alternative choice for seizure control in an emergency setting. However, no sufficient reports are available on buccal midazolam administration. The present study was designated to examine the efficacy of buccal midazolam in children at different ages with seizures of more than 5 min duration. Nineteen previously unreported children, aged from 1 month to 15 years, were treated with a 0.3 mg/kg dose of buccal midazolam; 13 had prolonged seizures, and six had status epilepticus, with a duration of 5-45 min (mean 22 min). Sixteen of 19 seizures (84.2%) stopped within 10 min of buccal midazolam being given. The drug efficacy in patients with status epilepticus was 50%. However, all patients with convulsions shorter than 30 min showed a perfect response (100%). Convulsion episodes stopped within 3.89 +/- 2.22 min (median time 3 min). Seizure duration was correlated with cessation of seizure (r = 0.76, P < 0.001). No clinically important side effects were seen in any patient. On the basis of this experience, we concluded that a 0.3 mg/kg dose of buccal administration of midazolam might offer an effective treatment in all ages of children. (C) 2002 Elsevier Science B.V. All rights reserved.en_US
dc.identifier.doi10.1016/S0387-7604(02)00230-9
dc.identifier.endpage278en_US
dc.identifier.issn0387-7604
dc.identifier.issue4en_US
dc.identifier.pmid12767460en_US
dc.identifier.scopus2-s2.0-0037614694en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage275en_US
dc.identifier.urihttps://doi.org/10.1016/S0387-7604(02)00230-9
dc.identifier.urihttps://hdl.handle.net/11616/93523
dc.identifier.volume25en_US
dc.identifier.wosWOS:000183394800011en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofBrain & Developmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectmidazolamen_US
dc.subjectbuccalen_US
dc.subjectseizureen_US
dc.subjectemergencyen_US
dc.subjectchilden_US
dc.titleBuccal midazolam for treatment of prolonged seizures in childrenen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu